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Abstract
Purpose of Review—Sleep plays many roles in maintenance of cardiovascular health. This 
review summarizes the literature across several areas of sleep and sleep disorders in relation to 
cardiometabolic disease risk factors.
Current Findings—Insufficient sleep duration is prevalent in the population and is associated 
with weight gain and obesity, inflammation, cardiovascular disease, diabetes, and mortality. 
Insomnia is also highly present and represents an important risk factor for cardiovascular disease, 
especially when accompanied by short sleep duration. Sleep apnea is a well-characterized risk 
factor for cardiometabolic disease and cardiovascular mortality. Other issues are relevant as well. 
For example, sleep disorders in pediatric populations may convey cardiovascular risks. Also, sleep 
may play an important role in cardiovascular health disparities.
Summary—Sleep and sleep disorders are implicated in cardiometabolic disease risk. This review 
addresses these and other issues, concluding with recommendations for research and clinical 
practice.
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INTRODUCTION
Sleep is responsible for many regulatory and maintenance functions in human physiology. 
Although this has been well-established, the specific mechanisms of these functions, and the 
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relation of this physiology to relevant clinical outcomes, has only more recently received 
increased attention. With this in mind, much recent work has focused on the role of sleep in 
the maintenance of cardiometabolic health. This includes laboratory, clinical, and 
epidemiologic research, focusing on issues such as insufficient sleep and sleep disorders 
such as sleep apnea and insomnia. Also, research has focused on issues pertaining to special 
groups, such as pediatric populations and racial/ethnic minorities. This review summarizes 
the work in these areas and proposes some considerations for addressing sleep duration and 
sleep disorders in the context of preventing cardiovascular disease.
HABITUAL SLEEP DURATION AND CARDIOVASCULAR DISEASE
Recently, the American Academy of Sleep Medicine and the Sleep Research Society jointly 
established a consensus panel to determine recommended guidelines for sleep duration. As a 
result of this process, a final guideline document was released(1-3) in addition to a 
companion manuscript that detailed methodological and other considerations(4, 5). In a 
parallel effort, the National Sleep Foundation developed its own guideline document(6) and 
companion manuscript(7). Both of these efforts agreed that a typical adult should get at least 
7 hours of sleep on a typical night in order to maintain optimal health and functioning. (The 
document by the National Sleep Foundation also suggested an upper limit of 9 hours.) The 
American Thoracic Society also recently released a document that made a similar 
statement(8). Taken together, these documents identify 7 hours as the minimum amount of 
habitual sleep duration that is recommended for health and functioning. As a part of all of 
these efforts, the respective panels examined a growing body of literature that identifies 
associations between insufficient habitual sleep duration and cardiometabolic disease risk.
Prevalence of insufficient sleep
Data from two survey cycles (2005-2006 and 2007-2008) of the National Health and 
Nutrition Examination Survey (NHANES) show that adults aged 20-39 and adults aged 
40-59 reported sleeping less than 7 hours in a 24 hour period more frequently (37.0% and 
40.3% respectively) than those aged over 60 years (32%)(9). These results are further 
supported by a recent CDC report, utilizing data from the Behavioral Risk Factor 
Surveillance System, that over 30% of US adults report less than 7 hours of habitual sleep 
duration(10).
Rather than being distributed evenly across the geographic landscape, Grandner and 
colleagues found unevenness in the distribution of such phenomenon. Using county-level 
data from the 2009 Behavioral Risk Factor Surveillance System (BRFSS), Grandner et al. 
identified insufficient sleep ‘hotspots’ in the Appalachian region that connects Tennessee, 
Virginia, West Virginia, Kentucky, and Ohio. Similar hotspots were found in the Midwest 
and southeast United States(11).
Sleep duration, cardiovascular events and mortality
Sleep duration and mortality are associated in a U-shaped fashion, where lowest risk is 
usually found in those who sleep between 7-8 hours, and mortality risk increasing with 
further deviation on either end of the range. This pattern of findings has been explored in 
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multiple narrative reviews(12, 13) and meta-analyses(14, 15). Mechanisms for this 
relationship are still not completely delineated, but short sleep duration has been linked to 
chronic illness, cardiovascular disease (CVD), increased BMI and risk for obesity, accidents, 
hypertension, hypercholesterolemia heart attack and stroke(12, 16-26) [3-11]. To investigate 
the association between short and long sleep duration and total CVD and coronary heart 
disease incidence, Hoevenaar-Blom et al. conducted a 12-year prospective study of 20,432 
healthy men and women in the Netherlands and found that those individuals who slept ≤6 
hours had a 15% higher risk of CVD incidence and a 23% higher risk of CHD incidence 
compared to people who slept 7-8 hours. When sleep quality was compared, individuals 
with short sleep duration and poor subjective sleep has a 63% higher risk of CVD and 79% 
higher risk of CHD than those with normal sleep duration and good sleep quality(22). In 
another relevant study, Altman and colleagues examined data from the 2009 BRFFS and 
found that short sleep duration was associated with elevated prevalence of hypertension, 
hyperlipidemia and history of heart attack and stroke(16).
Sleep duration and obesity
While the relationship between sleep duration and BMI can vary across age and age-related 
sleep need(19), insufficient sleep has been linked to lower energy expenditure, altered 
glucose homeostasis and alterations in hormones that mediate hunger(24, 25, 27-31). 
Altered sleep patterns may also be tied to lifestyle choices that are related to higher BMI and 
obesity(32). One possible mechanism for this could be explained by the metabolic hormones 
leptin and ghrelin. Leptin is secreted by adipose cells and it acts on the hypothalamus by 
regulating appetite through hunger inhibition. In laboratory sleep deprivation studies, 
decreased leptin secretion has been shown(26, 33). Ghrelin is a neuropeptide produced in the 
gastrointestinal tract. It acts on hypothalamic cells to increase hunger and has been shown to 
be increased in deprived sleep states in laboratory studies(26, 28, 33). This hormonal 
interaction may lead to an eating pattern that may lead to a dysregulation of energy balance 
through appetite stimulation that might predispose to cardiometabolic disease and weight 
gain. Along with the situational aspect of being awake longer leading to increased calorie 
intake, sleep deprived individuals are prone to indulge in late night snacks and make 
unhealthy food choices(34-40).
Sleep duration and behavioral risk factors
A variety of behavioral risk factors have been positively linked to insufficient sleep, such as 
unemployment, increased alcohol consumption, self-reported poor mental health days, and 
active cigarette smoking(41, 42). Additionally, sleep deprivation leads to cognitive 
impairment and reduced attention(43-46). Chronic sleep insufficiency has played a role in 
motor vehicle accidents, industrial disasters, medical and other occupational errors, for 
instance(41, 42, 47-51). Others have found that short self-reported sleep duration is 
associated with risk of depression(4, 52-54), the same association has been found for long 
sleepers (>8-9 hours) (13).
Sleep duration and inflammation
Inflammation is a well-established key mechanism in CVD risk and could be a possible 
mechanism linking sleep duration and CVD(55). Sleep deprivation has been associated with 
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increased inflammation and negative cardiovascular outcomes. Proinflammatory processes 
that promote the development of atherosclerotic plaques and Proinflammatory markers (such 
as tumor necrosis factor α [TNFα], interleukins 1 (IL-1), 6 (IL-6), and 17 (IL-17), C-
reactive protein (CRP), cellular adhesion molecules, and visfatin) have demonstrated or 
suggested an association with sleep deprivation in laboratory studies(55). Cytokines 
(specifically IL-6) and elevated CRP are a clinically useful measure of systemic 
inflammations that have been shown to be present in healthy individuals exposed to partial 
and total sleep deprivation(56).
A recent meta-analysis did not find a consistent association between short sleep and 
inflammation(57). A study using the 2007-2008 NHANES(56) (not included in that meta-
analysis) and a subsequent review(55) present some potential explanations. For example, 
using the 2007-2008 NHANES, levels of CRP were distributed in a U-shape across the US 
population. A few elements of this relationship suggest reasons why other studies could not 
find this relationship. First, these elevations were only seen at the extreme ends of the sleep 
duration spectrum (<5 and >9 hours), which most studies are not powered to examine. 
Second, there were significant race/ethnicity and sex patterns, suggesting that the makeup of 
the sample also played a role in findings. Third, since CRP does not demonstrate a circadian 
rhythm(58), a single measurement (common in epidemiologic studies) is more appropriate 
for this analyte. Finally, the NHANES sample may be one of the few samples that is 
sufficiently large and diverse (regarding age, sex, race/ethnicity, and geography) to detect the 
elevation associated with short sleep.
Sleep duration and Diabetes Mellitus (DM) risk
Sleep deprivation alters glucose homeostasis, leading to insulin resistance and risk of 
diabetes(17, 18, 24, 59-61). Sleep extension in restricted sleepers may lessen this 
relationship by improving glucose tolerance(17). Current research is exploring mechanistic 
pathways involved, including adipose tissue physiology and the role of circadian genetics.
In the Western New York Health Study, Rafalson and colleagues found that sleep duration 
<6 h was associated with impaired fasting glucose [30]. In another study, Shankar and 
colleagues found that self-reported insufficient sleep was positively associated with 
prevalence of Diabetes(62). In a cross sectional study, Hall et al. found that both short (>7h) 
and long sleepers (>8) were associated with metabolic syndrome in midlife adults despite 
adjusting for traditional risk factor components(63).
Several reviews on this topic have been published elsewhere(24, 60, 64, 65), including 
several meta-analyses(3, 66-69), which show that habitual short sleep duration was 
associated with a 30-50% increased incidence of diabetes.
Sleep duration and blood pressure
In a study of ambulatory blood pressure in 18 healthy subjects, Lusardi and colleagues 
observed that when sleep was restricted to the second half of the night for only a week, 
elevated diastolic and systolic blood pressure were present, compared to the week prior 
where a typical night of sleep was observed with no alterations(70).
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At the population level, Altman and colleagues found increased risk of hypertension 
associated with both short (≤5-6 hours)(16). In an analysis of the 2004–2005 NHIS data, 
Buxton and Marcelli found that short sleep duration is associated with increased prevalence 
of hypertension and CVD(21). Using the 2007-2008 NHANES data, Grandner and 
colleagues established an association between short sleepers and elevated risk for self-
reported history of hypertension, but not recorded blood pressure(20).
Sleep duration and lipids
Increased CVD morbidity risk is tied to a decrease in High-Density Lipoprotein (HDL) and 
an increase in Low-Density lipoprotein (LDL). This relationship might be mediated by age 
and gender, as lipoprotein metabolism is strongly associated with sex hormones. In one 
study, elevated triglyceride and LDL profiles were found in Japanese women who slept <6 
hours and >8 hours and were lowest among women who slept 6-7 hours. Risk of high LDL 
was low in men sleeping ≥8 hours(71). Short sleep duration has also been identified as a risk 
factor for hyperlipidemia and hypercholesterolemia in adolescents(72). Although a different 
study found relationships to hyperlipidemia only in very short sleepers, this association was 
most evident in non-Hispanic whites and Asians/others(20). It should be noted that in this 
study population, women were less likely to report as short or long sleepers. Very short sleep 
(>5) and increased incidence of hyperlipidemia was also found by Altman et al(16).
Taken together, habitual short sleep duration is highly prevalent in the US population. 
Regarding cardiometabolic risk, short sleep duration (6 hours or less), and especially very 
short sleep duration (less than 5 hours) is associated with increased cardiometabolic 
morbidity and mortality, including weight gain and obesity, hypertension, hyperlipidemia, 
and diabetes.
SLEEP APNEA AND CARDIOVASCULAR DISEASE
Prevalence of Sleep Apnea
In a recent review of 11 published epidemiological studies, the prevalence of obstructive 
sleep apnea (OSA), defined as an Apnea-Hypopnea Index (AHI) greater or equal to 5, was 
estimated to be 22% in men and 17% in women(73). More recent studies indicate that this is 
increasing, with an estimated prevalence of 37% in men and 50% in women(74, 75). The 
reason for the rising prevalence is thought to be secondary to differences in diagnostic 
equipment, the definition of OSA, study design, and patient characteristics such as age and 
obesity.(73) The prevalence of OSA in obesity is about 50% (76), with much higher 
prevalence in morbidly obese individuals.(77)
Drager and colleagues, studied 152 consecutive patients with metabolic syndrome (MetS) 
with a standard polysomnogram (PSG) and found the prevalence of moderate-severe sleep 
apnea, defined as an AHI greater than or equal to 15, to be about 60%. Patients with MetS 
and OSA were found to have greater cardiometabolic morbidity in comparison with those 
without OSA.(78)
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Obstructive sleep apnea (OSA) and cardiovascular mortality
The association between OSA and cardiovascular mortality is complicated due to associated 
factors such as obesity, insulin resistance, and dyslipidemia. However, OSA is an 
independent risk factor for atherosclerotic heart disease(79). Epidemiological data supports 
the idea that OSA can initiate not only cardiovascular conditions such as hypertension and 
ischemic heart disease but also worsen existing disease(80).
The key pathology resulting in the adverse cardiovascular outcomes stems from the 
intermittent hypoxia, hypercapnia, intrathoracic pressure changes and the resulting 
autonomic changes(80). The intermittent hypoxia induces oxygen free radical production 
and sets off an inflammatory response, over time causing adverse cardiovascular damage(81, 
82).
A prospective study from Punjabi and colleagues, showed increased all-cause mortality, 
specifically from coronary artery disease, in men aged 40-70 years with severe OSA 
characterized by apnea-hypopnea index (AHI) of greater than 30(83). Similar results were 
noted in an observational study where severe OSA was linked to an increased risk of fatal 
cardiovascular events (odds ratio of 2.87; 1.17 – 7.51) as well as non-fatal cardiovascular 
events (odds ratio of 3.17, 1.12 −7.51) compared to a control of healthy individuals(84). The 
intermittent hypoxia-hypercarbia results in myocardial oxygen demand-supply mismatch 
and can trigger nocturnal angina as well as ischemic electrocardiographic (EKG) 
changes(85).
OSA is a common treatable cause of drug-resistant hypertension(86). Independent of 
confounders, the odds of developing hypertension was 2.89 (95% CI; 1.46 −5.64) for 
patients with an AHI of >15 compared to the control group(87). A higher prevalence of 
arrhythmias such as paroxysmal supraventricular tachycardia and atrial fibrillation is noted 
in patients with OSA. An observational study reported patients with untreated OSA had 
twice the risk of recurrence of atrial fibrillation compared to the group who were treated 
with Continuous Positive Airway Pressure (CPAP) therapy(88).
Patients with congestive heart failure can have a component of central sleep apnea atop their 
obstructive component(89). Mansfield and colleagues, in a randomized trial, showed that 
patients treated with CPAP in addition to standard heart failure therapy had improved 
ejection fraction as well as improved quality of life(90). Similar results were noted by 
Kaneko et al., who noticed an improvement in ejection fraction as well morning blood 
pressures with CPAP treatment. This improvement was observed as early as one month from 
the initiation of CPAP therapy(91). Promising results were also noted by Ryan and 
colleagues who reported a 58% reduction in the frequency of ventricular arrhythmias during 
sleep in patients with OSA and heart failure(92).
A prospective observational study involving patients with CAD and moderate OSA with 
AHI >15 showed patients on CPAP had a significantly decreased cardiovascular mortality, 
acute coronary syndrome, hospitalization from heart failure exacerbation as well as need for 
coronary revascularization compared to the group which did not use the CPAP(93). Hence, a 
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consistent finding is that there is an improved cardiovascular outcome with regular use of 
CPAP in patients with OSA.
Syndrome Z and Metabolic Syndrome
Syndrome Z describes the association between OSA and metabolic syndrome (MetS). The 
odds for the presence of MetS in OSA ranges from five to nine fold when compared to 
individuals without OSA.(94) OSA may be an independent risk factor for metabolic 
syndrome.(95)
Sleep Apnea and Heart Failure
The prevalence of OSA among heart failure patients is about 30-50% while that of central 
sleep apnea (CSA) is about 25-40%. The presence of Congestive heart failure (CHF) may 
exacerbate or contribute to the development of OSA(96). Nocturnal fluid shift rostrally from 
the lower extremity towards the neck is believed to contribute to the pathogenesis of both 
OSA and CSA.(97)
Episodes of apnea and hypopnea related to pharyngeal collapse associated with OSA leads 
to negative inspiratory intrathoracic pressure. As a consequence, the venous return to heart 
increases increasing the right ventricular (RV) preload. Intermittent hypoxia, causes 
pulmonary vasoconstriction and hence increases RV after load. This may lead to the 
development of pulmonary hypertension and RV dysfunction. The post apneic related 
increase in sympathetic drive can persist during the day and lead to neurohormonal 
dysregulation and can adversely affect cardiac remodeling(96). Patients with HF may not 
present with typical symptoms of sleep apnea, such as excessive daytime sleepiness due to 
the heightened sympathetic activity(98). Intermittent hypoxia results in oxidative stress and 
release of inflammatory mediators involved in the progression of atherosclerosis. Wang and 
colleagues, in a study of patients with HF to determine the effect of untreated moderate to 
severe OSA versus mild to no OSA, found that the mortality was significantly higher in the 
untreated moderate to severe OSA group(99). Treatment with CPAP therapy has been shown 
to improve left ventricular ejection fraction, functional class, reduce hospitalization and 
consequently survival.(96)
Patients with HF have a high prevalence of Central sleep apnea (CSA). Cheyne stokes 
respiration (CSR), a pattern of breathing characterized by a cyclic crescendo decrescendo 
pattern of hyperventilation followed by apnea in the absence of upper airway 
obstruction(100). CSR in low output HF is thought to be due to an impaired feedback 
mechanism with delayed messaging to the respiratory control center resulting in respiratory 
oscillation in response to a fluctuating PCO2 level(101). The presence of wake hypocapnia, 
as demonstrated on an arterial blood gas may help predict the presence of CSR during sleep.
(101) Treatment consists of targeted optimization of medical therapy to HF status. CPAP 
improves CSR by multiple mechanisms, such as by increasing lung volume, stabilization of 
the upper airway, and improved oxygenation and cardiac function.(102)
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Sleep Apnea and Diabetes Risk
The prevalence of OSA in patients with history of diabetes mellitus (DM) ranges from 
58-87%.(94) OSA has been linked with increased risk of developing DM due to deregulation 
of glucose metabolism and alteration in the hypothalamic –pituitary adrenal axis (HPA) 
axis(103, 104). Intermittent hypoxia and sleep fragmentation related to OSA have been 
shown to independently increase insulin resistance, increase sympathetic activity and serum 
cortisol, and impair glucose clearance(94, 105) . The severity of OSA has a direct 
correlation with the worsening of glucose metabolism. In a study done to assess the effect of 
the severity of OSA and glycemic control by measurement of Hemoglobin A1c, it was found 
that HbA1c increased by 1.49% in mild OSA, 1.93% in moderate OSA, and 3.69% in severe 
OSA, compared with individuals without OSA.(106)
Improvement in glycemic control has been demonstrated after 3 months of CPAP use, with 
improvement related to number of hours of nightly CPAP use(107, 108). In a recent 
randomized control trial, patients who received CPAP when compared to the control group 
who did not receive CPAP were found to have improved glucose control and insulin 
sensitivity.(109) Also, CPAP therapy has been shown to improve insulin sensitivity in 
patients with OSA with or without diabetes(110, 111).
Sleep Apnea and Hypertension
Epidemiologic studies support the strong relationship between OSA and hypertension.(112) 
The prevalence of OSA in individuals with hypertension is estimated to be about 
40-50%(112) and approaches 83% in patients with resistant hypertension(86). In a large 
prospective longitudinal study on participants of the Wisconsin sleep cohort study, the odds 
for the presence of hypertension were 2.03 for apnea-hypopnea index (AHI) between 5.0 to 
14.9 events per hour and 2.89 for AHI greater than 15 events per hour(113). Epidemiologic 
studies suggest the relationship between hypertension and OSA to be bidirectional. 
Activation of the sympathetic nervous system and renin-angiotension-aldosterone system, 
along with oxidative stress and endothelial dysfunction, implicate OSA as an independent 
risk factor for the development of hypertension. Inhibition of upper airway muscles, volume 
overload and rostral shift of fluid nocturnally can contribute to pharyngeal edema and the 
development of OSA in hypertensive patients.(114)
Schein and colleagues performed a recent met analysis and systematic review of 16 RCTs 
involving over 1000 patients, to study the effects of CPAP therapy on hypertension in OSA 
patients. Modest reduction in mean systolic blood pressure (SBP) (−4.92 mm Hg; 95%CI 
−8.70 to −1.14) and mean (−2.56 mm Hg; 95% CI −4.43 to −0.68 mmHg) nighttime blood 
pressure were seen. No significant change in daytime SBP (−0.74 mm Hg; 95% CI −3.9 to 
2.41) and daytime diastolic blood pressure (−1.86 mm Hg; 95% CI −4.55 to 0.83) were 
observed, however.(115)
The effect of CPAP therapy is more pronounced in patients with resistant hypertension. In a 
recent meta-analysis, to study the effect of CPAP therapy on OSA patients on this subset of 
patients, showed the mean improvement of ambulatory SBP and DBP of −6.74 mm Hg 
(95% CI −9.98 to −3.49;P value <0.001) and −5.94 mm Hg (95% CI;-9.40 to 
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−2.47;P=0.001) respectively(116). The improvement correlated with the duration of CPAP 
use. Blood Pressure improved by 1.3 mm Hg for each additional hour of CPAP use.(117)
Sleep Apnea and Dyslipidemia
Murine experiments reveal that it is the intermittent hypoxia which upregulates triglyceride 
and phospholipid synthesis and inhibits cholesterol uptake in the liver resulting in 
dyslipidemia(118, 119). OSA has been associated with dyslipidemia and its associated 
higher CV mortality. However, the causal relation between OSA and dyslipidemia remains 
to be elucidated due confounders such as obesity, diet, and physical activity.
The evidence is limited to cross-sectional studies and a few randomized studies. The major 
limitation of all these studies being their duration of follow-up. The majority of the studies 
indicate that the total cholesterol and LDL were unchanged. However, an increase in 
triglyceride levels and decrease in the HDL levels were noted in patients with OSA(120, 
121). Non-randomized trials studying the effects of treatment of OSA with CPAP revealed a 
decrease in total cholesterol, LDL, homocysteine, and triglycerides, while on treatment; 
however, there was mixed data on HDL(122-127). Robinson and colleagues demonstrated a 
decrease in total cholesterol while on treatment with CPAP(128). Similarly, Phillips and 
colleagues, in a randomized, placebo-controlled trial looking at the role of CPAP on 
postprandial lipid levels in patients with OSA, concluded that treatment of severe OSA with 
CPAP improved postprandial triglyceride levels as well as total cholesterol levels(129). 
These trials, although randomized, have limitations such as a lack of adjustment for CPAP 
adherence and the role of lipid-lowering medications. An observational study in Portugal 
followed patients for an eight year period and concluded that CPAP treatment improves 
daytime sleepiness in patients with OSA but does not play as significant a role in improving 
their lipid profile comparable to the lipid-lowering medications(130). Although a direct 
causal relation of OSA and dyslipidemia is yet to be determined, there is increasing evidence 
that an association exists(131). The actual impact of the treatment of OSA in the 
improvement of the lipid profile is debatable and will require large RCTs.
INSOMNIA AS A CARDIOVASCULAR DISEASE RISK FACTOR
Insomnia has long been viewed as a symptom of the “worried well.” However, accumulating 
evidence indicates that insomnia disorder is a significant risk factor for CVD(132, 133). 
Insomnia, especially when coupled with short sleep duration, is associated with 
hyperactivity of the hypothalamic-pituitary-adrenal axis (e.g., increased cortisol secretion) 
and sympathetic system (e.g., impaired heart rate variability) and, consequently, with a 
clinically significant risk of CVD (e.g., hypertension, type-2 diabetes, myocardial infarction, 
and coronary heart disease).
Epidemiology of Insomnia: Scope of the Problem
The prevalence of insomnia in the general population ranges between 8-40%, depending on 
the definition used. While 20-30% of the general population has “poor sleep” (i.e., difficulty 
falling asleep, staying asleep, early morning awakening or non-restorative sleep at any given 
time), another 8-10% of the population has insomnia(134, 135).
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Natural history studies indeed show that insomnia is a highly persistent condition, whereas 
the course of “poor sleep” is more unstable and likely to remit(136-140), which indicates 
that insomnia is a disorder while “poor sleep” is a symptom of underlying physical or mental 
health problems(137, 138, 140). Despite the fact that the objective sleep of people with 
insomnia is different than that of normal sleepers(135, 141) and that objective short sleep 
duration has been shown to predict the development of “poor sleep” into insomnia(138) and 
the persistence of insomnia(140), polysomnographic (PSG) studies are not required for the 
diagnosis of insomnia(141), which contrasts with the current indication of PSG for the 
evaluation of patients with sleep disordered breathing and their associated CVD risk. 
Actually, the associations between insomnia and significant CVD risk has not been 
systematically examined until recently.
Insomnia as a Behavioral Risk Factor
Insomnia may be associated with increased CVD risk through its association with poor 
health behaviors. Indeed, individuals with “poor sleep” or insomnia are more likely to report 
increased alcohol and caffeine use, smoking, and lack of physical activity and to show lower 
cardiorespiratory fitness as compared to normal sleepers(142). Moreover, individuals with 
insomnia may be at increased CVD risk through poor diet, as subjective and objective sleep 
has been associated with dietary macronutrient and micronutrient composition(143). For 
example, a recent study of the 2007-2008 National Health and Nutrition Examination Survey 
(NHANES) found inadequate intake of alpha-carotene, calcium, selenium, salt, 
carbohydrates, vitamin D, lycopene, dodecanoic, hexadecanoic, butanoic or hexanoic acids 
to be associated with “poor sleep”(144). It is likely that the relationship between insomnia 
and “poor sleep” with many of these health behaviors is bidirectional(137, 138, 140). 
Interestingly, however, sleep hygiene therapy alone, which targets poor health behaviors, is 
not effective in the treatment of insomnia. Importantly, most studies on the independent 
association of insomnia with CVD risk have controlled for alcohol and smoking but not diet 
or physical activity. More work is needed to establish the relative contribution of health 
behaviors to the CVD risk associated with insomnia.
Insomnia Pathophysiology and Cardiovascular Risk
Current models of insomnia posit the joint effect of stressful life events(145) and stress-
related psychological factors as central to the pathogenesis of insomnia(146, 147); thus, 
activation of the stress system, i.e., hypothalamic-pituitary-adrenal (HPA) axis and 
sympathetic nervous system, should be a key pathophysiologic mechanism of the persistence 
of insomnia. While early studies reported no difference between “poor sleepers” and 
controls in cortisol levels, later studies found that 24-h urinary free cortisol, norepinephrine, 
and catecholamine metabolites levels were increased in patients with insomnia or were 
correlated with PSG indices of sleep disturbance in insomnia patients(148-151). Also, other 
studies, with a few exceptions(152-155), have found that insomnia is associated with 
increased nocturnal heart rate, blunted heart rate variability (HRV)(156-160), altered 
sympathovagal balance, as measured by impedance cardiography(156, 161), increased 
overall oxygen consumption (VO2), a measure of increased whole-body metabolic rate(162, 
163), increased pupil size, indicative of sympathetic system activation(164), increased 
central nervous system activation during sleep(165-167), increased or altered systemic 
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inflammation(57, 168), and increased daytime sleep latencies in the Multiple Sleep Latency 
Test (MSLT), a test of physiologic sleep propensity(155, 169). The shorter the objective 
sleep duration, the longer the sleep latencies in the MSLT in persons with insomnia(170, 
171).
In summary, increased peripheral and central markers of HPA axis dysfunction and 
sympathetic activation are primarily found in insomniacs with objective short sleep duration, 
who suffer from a disorder of 24-hour hyperarousal(172). Thus, proposed physiologic 
mechanisms of the association of insomnia with CVD risk include neuroendocrine 
dysregulation, autonomic imbalance, and increased inflammation.
Insomnia and Cardiovascular Disease Risk
Although the association of insomnia with cardiovascular disease has been reported for 
several years(173), its association with clinical risk factors (e.g., hypertension, diabetes, 
metabolic syndrome) and cardiovascular disease has remained largely unexplored until 
recently(174). In fact, only in the past few years several systematic reviews and meta-
analyses have been published on the association of insomnia with CVD risk. For example, 
the estimated risk for incident hypertension associated with “poor sleep” or insomnia ranges 
between 5% and 20%(175), that for type-2 diabetes (T2D) about 57%(3), and that for 
incident myocardial infarction (MI) and coronary heart disease (CHD) between 41% and 
55%, respectively(176, 177). Although these studies have shown a significant association 
between insomnia, mainly “poor sleep”, and CVD risk, the effect sizes reported were modest 
and most studies did not include PSG and could not control for SDB.
Based on the physiologic mechanisms reviewed above, recent work from the Penn State 
Adult Cohort has shown a synergistic effect between insomnia and PSG-measured short 
sleep duration (i.e., < 6 hours) on the risk for hypertension and T2D even after controlling 
for multiple confounders, including SDB(178-180). Specifically, the odds of T2D in 
individuals with insomnia who slept < 6 hours were 2.1- to 3.0-fold cross-sectionally and the 
odds of hypertension were 3.5- to 5.1-fold cross-sectionally71 and 3.8-fold longitudinally, 
while the odds of hypertension or T2D in individuals who reported insomnia but slept 
objectively > 6 hours were not significantly increased (e.g., OR = 1.3 and 0.85). Importantly, 
these findings have been replicated in two recent studies in patients with insomnia using 
PSG-measured short sleep duration(181) and MSLT-measured increased sleep latency(182).
While SDB is strongly associated with the metabolic syndrome (MetS), the evidence for 
insomnia is limited and inconsistent(63, 183, 184). A potential explanation may be related to 
different physiologic mechanisms in SDB and insomnia; for example, central obesity is 
strongly associated with incident SDB and “poor sleep”, but not as much with incident 
insomnia. In fact, patients with insomnia are typically non-obese(185) and in a recent 
longitudinal study(186), despite sleeping objectively shorter than controls or “poor 
sleepers”, non-obese insomniacs were less likely to become obese than controls or “poor 
sleepers”, a finding consistent with the presence of increased whole-body metabolic 
rate(162). These data indicate that insomnia with short sleep duration may be linked to 
insulin resistance and CVD independent of central obesity.
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Current literature indicates that insomnia is a premorbid risk factor of CVD. Accumulating 
evidence suggests that the association of insomnia with CVD risk is more pronounced when 
insomnia is associated with objective short sleep duration or other measures of physiologic 
arousal. Evidence suggests that measures of insomnia, and especially objective sleep 
measures, should be included in the estimation of CVD risk in the clinical and general 
population.
SLEEP AND CARDIOVASCULAR DISEASE RISK IN PEDIATRICS
Factors that increase cardiovascular risk have been shown to emerge early in life. For 
example, blood pressure and body mass index in adolescence predict future adult 
cardiovascular risk (187). Similar to what has been shown in adults; sleep-related factors are 
important contributors to cardiovascular risk in childhood. These factors include both sleep 
duration, as well as factors that disrupt sleep quality, particularly sleep-disordered breathing.
Sleep duration and cardiovascular disease risk in children
Sleep curtailment and short sleep duration have been linked to increased adiposity and 
elevated BMI in longitudinal studies spanning from infancy to adolescence (188, 189). 
Additionally, there is robust evidence linking short sleep duration to impaired glucose 
metabolism. A recent study showed that shorter sleep duration, as well as worse sleep 
efficiency, was associated with impaired glucose tolerance (190). This is consistent with 
most prior literature, which generally has shown that short sleep in children and adolescents 
is associated with impaired glucose metabolism (191). One prior study identified a U-shaped 
relationship, with short and long sleep duration both predicting impaired glucose tolerance, 
similar to adults (192). A recent cross-sectional study has also identified that short sleep 
duration in obese children is associated with elevated homocysteine levels compared to 
obese children who obtain sufficient sleep (193).
Pediatric sleep-disordered breathing and cardiovascular disease risk
SDB is a prevalent condition in children, with obstructive sleep apnea seen in 1.2-5.7% of all 
children (194). In children with cardiovascular risk factors, the prevalence may be even 
higher. A recent retrospective study found that 55% of children with hypertension referred 
for polysomnography were found to have sleep-disordered breathing (195). Sleep-disordered 
breathing in children is associated with adverse cardiovascular effects including 
dysregulation of blood pressure (196, 197) and cardiac dysfunction (198, 199). Children 
with sleep-disordered breathing have significantly elevated pulmonary arterial pressures as 
well as right ventricular hypertrophy and dysfunction (199). There is also evidence for left 
ventricular dysfunction (198). The underlying pathophysiologic effects of sleep-disordered 
breathing that may cause these deleterious effects include endothelial dysfunction (200), 
autonomic dysfunction (201), and chronic inflammation (202). Importantly, these adverse 
cardiovascular effects appear to be reversible with treatment (199). Sleep disordered 
breathing is also associated with significant metabolic adverse effects. The presence of OSA 
has been shown to be associated with increased serum triglycerides, blood glucose and 
insulin resistance (203).
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In general, recent evidence in children has continued to identify sleep as an important factor 
in cardiovascular risk. Both short sleep duration and sleep-disordered breathing appear to be 
important modifiable risk factors that contribute towards overall cardiovascular risk. 
Targeted sleep interventions during childhood may be an important strategy to lower 
cardiovascular risk throughout the lifetime.
SLEEP AND CARDIOVASCULAR HEALTH DISPARITIES
Cardiovascular Health Disparities as a Public Health Priority
Health disparities exist when one group of people is at a disadvantage as a virtue of their 
socioedemographic category and not inherent physiologic risk. In these cases, increased risk 
for morbidity and mortality are a product of social-environmental influences and as such 
represent a societal concern. Although health care advances have proceeded at a dramatic 
pace over the last half-century, racial/ethnic and socioeconomic health disparities are still 
well-documented in the United States.(204-206). In particular many racial/ethnic minority 
groups (particularly Blacks/African-Americans and Hispanics-Latinos) are at greater risk of 
obesity, heart disease, diabetes, and cardiovascular events (204, 206, 207). These effects 
persist even after accounting for socioeconomics (204, 206). It is likely that a complex 
combination of structural, physiological, psychological and behavioral differences drive 
these relationships (205, 206, 208-210). In addition, environmental factors such as 
neighborhood may play a significant role through differential exposures to social, 
psychological, and physical influences (211, 212). Understanding and reducing health 
disparities has been identified as a key public health priority(206, 213).
Sleep Disparities in the Population
Several studies have documented sleep disparities in the US population. A meta-analysis by 
Ruiter and colleagues(214) showed that Blacks/African-Americans obtained less 
polysomnographic sleep than Non-Hispanic Whites. Blacks/African-Americans also 
obtained less Slow Wave Sleep. Other studies have also found that Blacks/African-
Americans obtained less Slow Wave Sleep(215-219) and had poorer sleep efficiency(217, 
219) than Non-Hispanic Whites.
Several epidemiologic studies have examined population-level sleep disparities. Using the 
2007-2008 NHANES, Whinnery and colleagues(220) found that relative to non-Hispanic 
Whites, Blacks/African-Americans were 3.5 times as likely to report very short (<5 hours) 
sleep duration and twice as likely to report short (5-6 hours) sleep duration. In this same 
sample, non-Mexican Hispanics/Latinos were 87% more likely to report very short sleep and 
35% more likely to report short sleep. And Asians/Others were 2.5 times as likely to report 
very short sleep and 67% more likely to report short sleep. These findings are mirrored in 
many other studies, which have shown increased prevalence of habitual short sleep duration 
among racial/ethnic minority groups(221-225).
Regarding sleep disorders, Ruiter and colleagues(226) found that African-Americans were 
more likely to have sleep disordered breathing, of greater severity, compared to Whites. Data 
from the 2007-2008 NHANES(227) also showed that Blacks/African-Americans were more 
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likely to report sleep latency >30 minutes, but self-reported difficulties initiating or 
maintaining sleep were all reported less frequently among minority groups, suggesting that 
despite differences in sleep, these are not perceived as “difficulties.” In this sample, Non-
Mexican Hispanics/Latinos were more likely to report choking/gasping during sleep and 
snoring(228). Other studies have found inconsistent relationships between race/ethnicity and 
sleep symptoms. Although some studies have found that sleep quality is worse among racial/
ethnic minorities(229-232), others have not(233-235). A potential explanation is the 
variable, interactive roles of race/ethnicity, socioeconomic, and cultural factors.
Could Sleep be a Modifiable Risk Factor for Cardiovascular Health Disparities?
If racial/ethnic minorities are at increased risk of cardiometabolic disease, and if insufficient 
sleep is also associated with cardiometabolic disease, and if racial/ethnic minorities are more 
likely to experience insufficient sleep, it is plausible to suggest that sleep may play a role in 
disparities and therefore may serve as an intervention target. Although this has not yet been 
directly tested, several studies have shown that the relationship between sleep and 
cardiometabolic disease risk does depend on race/ethnicity. Knutson and colleagues(236) 
found that racial differences in 5-year blood pressure change were explained by differences 
in sleep duration. Also, Grandner and colleagues(56) found that the relationship between 
sleep duration and C-reactive protein (a cardiovascular risk marker) differed by race/
ethnicity. This was followed up by another analysis that showed that the relationship 
between sleep duration and obesity, diabetes, hypertension and hyperlipidemia depended on 
self-identified race/ethnicity(20).
PREVENTING CARDIOVASCULAR DISEASE: A ROLE FOR SLEEP 
DISORDERS SCREENING
Sleep disorders have been robustly implicated in cardiometabolic disease risk. In particular, 
sleep apnea is a well-characterized risk factor for cardiometabolic morbidity and even 
cardiovascular events. Strikingly, as described above, studies that evaluated the prevalence of 
sleep apnea in obesity, cardiology, and diabetes clinics routinely find that most patients meet 
criteria for sleep apnea, though few are diagnosed and even fewer are successfully treated. 
For this reason, clinics that treat patients with cardiovascular disease, diabetes, and/or 
obesity should routinely screen patients for sleep apnea risk and refer for diagnosis 
appropriately.
Insomnia is also shown to be an important marker of cardiometabolic disease risk. It is, 
however, often ignored in the context of treatment for these conditions. Screening for 
insomnia is not difficult, though, with brief instruments such as the Insomnia Severity 
Index(237) and other brief screening measures. Of note, the recommended first line 
treatment for insomnia is not pharmacotherapy, although pharmacotherapy remains the most 
widely-utilized approach(238). This particularly important since prescription hypnotic 
medications may carry significant risks(239-243). The recommended first-line treatment, 
Cognitive Behavioral Therapy for Insomnia (CBTI) does not carry these risks and is 
therefore preferable for reasons beyond demonstrated efficacy(244-248), efficacy relative to 
medications(249-253), and effectiveness(254). Despite this, knowledge about the existence 
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of CBTI is limited in the medical community, and providers may be difficult to locate(255). 
Still, patients with insomnia should be directed to CBTI when it is available.
PREVENTING CARDIOVASCULAR DISEASE: A ROLE FOR HEALTHY 
SLEEP DURATION
In addition to sleep disorders, it has been repeatedly shown that insufficient sleep duration is 
an important risk factor for cardiometabolic disease risk. In addition to many cross-sectional 
studies, prospective studies show that insufficient sleep is a risk factor for incident obesity, 
hypertension, and diabetes. For this reason (and others), achieving adequate sleep duration 
has been included as a Healthy People 2020 goal(213). This should be reflected in practice. 
Clinicians should be asking about sleep duration and consider short sleep duration among 
other behavioral risk factors such as poor diet, inactivity, smoking, and excessive alcohol 
use.
CONCLUSIONS
Over 50 years ago, epidemiologic studies began to show that habitual sleep was associated 
with mortality(256). Since that time, substantial knowledge about the role of sleep in 
cardiometabolic health has emerged. Habitual short sleep duration is associated with weight 
gain and obesity, hypertension, hyperlipidemia, inflammation, diabetes, heart attack, and 
stroke. Sleep apnea is associated with cardiac and vascular dysfunction, hypertension, 
dyslipidemia, diabetes, inflammation, heart attack and stroke. Even insomnia, which has 
been traditionally seen as relatively benign, is a risk factor for cardiometabolic morbidity 
and mortality. Taken together, sleep represents an important domain of cardiometabolic 
health risk. Future studies are needed to better characterize the mechanisms by which sleep 
leads to morbidity and to identify and refine interventions to better ameliorate this risk. In 
the meantime, healthy sleep should be a consideration in the clinical care of heart disease 
patients.
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- Insufficient sleep duration is prevalent in up to 1/3 of US adults and is 
associated with weight gain, diabetes, hypertension, inflammation, and 
mortality.
- Insomnia disorder is prevalent in 5-15% of US adults and is associated 
with cardiometabolic disease risk, especially when paired with objective 
short sleep duration.
- Sleep apnea is prevalent among men and women in the US and is a strong 
predictor of cardiometabolic morbidity and mortality, especially if left 
untreated.
- Pediatric sleep disorders such as insomnia and sleep apnea are related to 
cardiovascular disease risk.
- Sleep may play an important and potentially modifiable role in 
cardiovascular health disparities.
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